Deutsch, Julie Stein
Cimino-Mathews, Ashley
Thompson, Elizabeth
Provencio, Mariano
Forde, Patrick M. http://orcid.org/0000-0001-6925-6344
Spicer, Jonathan http://orcid.org/0000-0003-2708-1309
Girard, Nicolas
Wang, Daphne
Anders, Robert A. http://orcid.org/0000-0002-2363-9072
Gabrielson, Edward
Illei, Peter
Jedrych, Jaroslaw
Danilova, Ludmila http://orcid.org/0000-0003-2813-3094
Sunshine, Joel http://orcid.org/0000-0001-9987-6712
Kerr, Keith M.
Tran, Mia
Bushong, Judith http://orcid.org/0009-0003-8203-5759
Cai, Junliang
Devas, Vipul
Neely, Jaclyn
Balli, David
Cottrell, Tricia R. http://orcid.org/0000-0003-2952-1830
Baras, Alex S. http://orcid.org/0000-0003-2397-3342
Taube, Janis M. http://orcid.org/0000-0002-8273-4395
Article History
Received: 21 September 2023
Accepted: 23 October 2023
First Online: 30 October 2023
Competing interests
: J.S.D. reports being named on a patent for system and method for annotating pathology images to predict patient outcome (US Provisional Patent Application: 63/313,548; filed 2/24/2022). A.C.-M. reports receiving grants or contracts from Bristol Myers Squibb. M.P. reports receiving grants or contracts from AstraZeneca, Bristol Myers Squibb, Janssen, Pfizer, Roche and Takeda; and honoraria from AstraZeneca, Bristol Myers Squibb, MSD, Pfizer, Roche and Takeda. P.M.F. reports research funding received by his institution from AstraZeneca, BioNTech, Bristol Myers Squibb, Corvus, Kyowa, Novartis and Regeneron; trial steering committee membership for AstraZeneca, BioNTech, Bristol Myers Squibb and Corvus; participation in advisory boards and reimbursement from Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi, F-Star Therapeutics, G1 Therapeutics, Genentech, ITeos Therapeutics, Janssen, Merck, Novartis, Sanofi and Surface; and leadership positions at Mesothelioma Applied Research Foundation and LUNGevity Foundation. J. Spicer reports research funding received by his institution from AstraZeneca, Bristol Myers Squibb, CLS Therapeutics, Protalix Biotherapeutics, Merck and Roche; receiving support for the present manuscript from Bristol Myers Squibb; consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb, Merck, Novartis, Protalix Biotherapeutics, Regeneron, Roche and Xenetic Biosciences; honoraria from AstraZeneca, Bristol Myers Squibb and PeerView; participation on data safety monitoring/advisory boards for the PUCC trial; and leadership positions at the Canadian Association of Thoracic Surgeons (unpaid). N.G. reports receiving consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi and Takeda; and meeting/travel support from Roche. R.A.A. reports receiving support for the present manuscript from Bristol Myers Squibb; grants or contracts from RAPT Therapeutics; consulting fees from AstraZeneca and MSD; and meeting/travel support from Bristol Myers Squibb. E.G. reports research funding received by his institution from the National Cancer Institute and Congressionally Directed Medical Research Programs—Department of Defense; honoraria from the LUNGevity Foundation; expert testimony provided to Covington and Burling; and holding mutual funds and exchange traded funds. P.I. reports receiving support for the present manuscript from Bristol Myers Squibb; grants or contracts from Bristol Myers Squibb; consulting fees from AbbVie, AstraZeneca, Merus, Roche and Sanofi; honoraria from Bristol Myers Squibb, Eli Lilly and Genentech; and being a shareholder of Bristol Myers Squibb. J. Sunshine reports grants or contracts from Palleon Pharmaceuticals. K.M.K. reports consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Takeda and Ventana; and honoraria from AstraZeneca, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Medscape, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Prime Oncology, Roche and Ventana. M.T. is an employee and shareholder of Bristol Myers Squibb. J.B. is an employee and shareholder of Bristol Myers Squibb. J.C. is an employee and shareholder of Bristol Myers Squibb. V.D. is an employee and shareholder of Bristol Myers Squibb. J.N. is an employee and shareholder of Bristol Myers Squibb. D.B. is an employee and shareholder of Bristol Myers Squibb; and reports being named on a patent of Bristol Myers Squibb. T.R.C. reports research funding received by her institution from Janssen; and honoraria from AstraZeneca, Society for Immunotherapy of Cancer and TotalCME. J.M.T. reports receiving support for the present manuscript from Bristol Myers Squibb; consulting fees from AstraZeneca, Bristol Myers Squibb, Merck and Roche; participation on advisory boards from AstraZeneca; and being named on a patent for a machine learning algorithm for irPRC. The other authors declare no competing interests.